Literature DB >> 32341633

The Multiple Sclerosis Surveillance Registry: A Novel Interactive Database Within the Veterans Health Administration.

Mitchell T Wallin1, Ruth Whitham1, Heidi Maloni1, Shan Jin1, Jonathan Duckart1, Jodie Haselkorn1, William J Culpepper1.   

Abstract

OBJECTIVE: To demonstrate the infrastructure and utility of an interactive health system database for multiple sclerosis (MS), we present the MS Surveillance Registry (MSSR) within the US Department of Veterans Affairs (VA).
BACKGROUND: Disease specific databases can be helpful in the management of neurologic conditions but few are fully integrated into the electronic health record and linked to health system data. Creating a consistent information technology (IT) architecture and with ongoing support within disease specific registries has been a challenge.
METHODS: Building the MSSR was initiated by an iterative process with an IT team and MS health care providers. A common registry platform shared by other VA disease specific registries (eg, traumatic brain injury and cancer) was used to develop the IT infrastructure. MS cases were entered online into the MS Assessment Tool at selected MS Centers of Excellence (MSCoE) clinics in the US. Other large VA databases linked to MSSR are reviewed. Patient demographic and clinical characteristics were compared and contrasted with the broader VA population and other US registry populations.
RESULTS: We have enrolled 1,743 patients with MS in the MSSR through fiscal year 2019 from selected MS regional programs in the VA MSCoE network. The mean age of patients was 56.0 years, with a 2.7 male:female ratio. Among those with definite MS, the mean European Database for MS Disability Score was 4.7 and 75% had ever used an MS disease modifying therapy. A summary electronic dashboard was developed for health care providers to easily access demographic and clinical data for individuals and groups of patients. Data on comorbid conditions, pharmacy and prosthetics utilization, outpatient clinic visits, and inpatient admission were documented for each patient.
CONCLUSIONS: The MSSR is a unique electronic database that has enhanced clinical management of MS and serves as a national source for clinical outcomes.
Copyright © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2020        PMID: 32341633      PMCID: PMC7182245     

Source DB:  PubMed          Journal:  Fed Pract        ISSN: 1078-4497


  22 in total

1.  Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium.

Authors:  Ilya Kister; Eric Chamot; Joshua H Bacon; Gary Cutter; Joseph Herbert
Journal:  Mult Scler       Date:  2011-01-26       Impact factor: 6.312

2.  Data harmonization for collaborative research among MS registries: A case study in employment.

Authors:  A Salter; A Stahmann; D Ellenberger; F Fneish; W J Rodgers; R Middleton; R Nicholas; R A Marrie
Journal:  Mult Scler       Date:  2020-03-12       Impact factor: 6.312

Review 3.  Registers of multiple sclerosis in Denmark.

Authors:  N Koch-Henriksen; M Magyari; B Laursen
Journal:  Acta Neurol Scand       Date:  2015       Impact factor: 3.209

4.  Risk tolerance to MS therapies: Survey results from the NARCOMS registry.

Authors:  Robert J Fox; Amber Salter; Joan M Alster; Neal V Dawson; Michael W Kattan; Deborah Miller; Sneha Ramesh; Tuula Tyry; Brian W Wells; Gary Cutter
Journal:  Mult Scler Relat Disord       Date:  2015-03-26       Impact factor: 4.339

Review 5.  The MSBase registry: Informing clinical practice.

Authors:  Tomas Kalincik; Helmut Butzkueven
Journal:  Mult Scler       Date:  2019-05-23       Impact factor: 6.312

6.  The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Authors:  Antonio Scalfari; Anneke Neuhaus; Alexandra Degenhardt; George P Rice; Paolo A Muraro; Martin Daumer; George C Ebers
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

7.  Multiple sclerosis registries in Europe - results of a systematic survey.

Authors:  Peter Flachenecker; Karoline Buckow; Maura Pugliatti; Vanja Bašić Kes; Mario A Battaglia; Alexey Boyko; Christian Confavreux; David Ellenberger; Danica Eskic; David Ford; Tim Friede; Jan Fuge; Anna Glaser; Jan Hillert; Edward Holloway; Eva Ioannidou; Ludwig Kappos; Elisabeth Kasilingam; Nils Koch-Henriksen; Jens Kuhle; Vito Lepore; Rod Middleton; Kjell-Morton Myhr; Anastasios Orologas; Susana Otero; Dorothea Pitschnau-Michel; Otto Rienhoff; Jaume Sastre-Garriga; Tsveta Schyns-Liharska; Dragana Sutovic; Christoph Thalheim; Maria Trojano; Yan V Vlasov; Ozgür Yaldizli
Journal:  Mult Scler       Date:  2014-04-28       Impact factor: 6.312

8.  High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010).

Authors:  Elaine Kingwell; Feng Zhu; Ruth Ann Marrie; John D Fisk; Christina Wolfson; Sharon Warren; Joanne Profetto-McGrath; Lawrence W Svenson; Nathalie Jette; Virender Bhan; B Nancy Yu; Lawrence Elliott; Helen Tremlett
Journal:  J Neurol       Date:  2015-07-24       Impact factor: 4.849

9.  Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.

Authors:  Peter Alping; Fredrik Piehl; Annette Langer-Gould; Thomas Frisell
Journal:  Epidemiology       Date:  2019-03       Impact factor: 4.822

10.  Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Authors:  Sarah L Minden; R Philip Kinkel; Helene T Machado; Jonathan S Levin; Meredith B Rosenthal; Lisa I Iezzoni
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-02-20
View more
  2 in total

1.  NARCOMS and Other Registries in Multiple Sclerosis: Issues and Insights.

Authors:  Ruth Ann Marrie; Gary R Cutter; Robert J Fox; Timothy Vollmer; Tuula Tyry; Amber Salter
Journal:  Int J MS Care       Date:  2021-12-29

2.  Disease-modifying therapy prescription patterns in people with multiple sclerosis by age.

Authors:  Yinan Zhang; Amber Salter; Shan Jin; William J Culpepper; Gary R Cutter; Mitchell Wallin; Olaf Stuve
Journal:  Ther Adv Neurol Disord       Date:  2021-03-31       Impact factor: 6.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.